Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
63 hedge funds and large institutions have $19.3M invested in Asterias Biotherapeutics Inc. Series A in 2015 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 5 closing their positions.
480% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 5
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
62% more funds holding
Funds holding: 39 → 63 (+24)
15% more capital invested
Capital invested by funds: $16.7M → $19.3M (+$2.53M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $144K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$9.59M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.65M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.73M |
| 4 |
Millennium Management
New York
|
+$754K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$611K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$425K |
| 2 |
Goldman Sachs
New York
|
-$312K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$230K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$160K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Goldman Sachs
New York
| – | -$312K | -46,283 | Closed |
|
|
BCM
52
BlueCrest Capital Management
St Helier,
Jersey
| – | -$124K | -18,410 | Closed |
|
|
BAM
53
Brave Asset Management
Summit,
New Jersey
| – | -$3K | -393 | Closed |
|
54
Creative Planning
Overland Park,
Kansas
| – | -$1K | -200 | Closed |
|
|
W
55
Wealthfront
Palo Alto,
California
| – | +$29 | +3 | New |
|
|
CTC
56
Central Trust Company
Jefferson City,
Missouri
| – | +$38 | +4 | New |
|
|
GT
57
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$38 | +4 | New |
|
|
CPIG
58
Chicago Partners Investment Group
Chicago,
Illinois
| – | +$153 | +16 | New |
|
|
EWM
59
Endurance Wealth Management
Providence,
Rhode Island
| – | +$153 | +16 | New |
|
|
MFS
60
MSI Financial Services
Springfield,
Massachusetts
| – | +$326 | +34 | New |
|
AST Hedge Fund Activity: Q2 2015 in Review
63 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q2 2015, worth a combined $19.3M — up 15% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AST positions and 5 closed out — a net gain of 24 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $9.59M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $425K sold.
- 63 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q2 2015, up from 39 in Q1 2015.
- Funds reported $19.3M of Asterias Biotherapeutics Inc. Series A stock for Q2 2015, up 15% quarter-over-quarter.
- 29 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q2 2015 and 5 closed out, a net change of +24 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q2 2015 was Broadwood Capital, an estimated $9.59M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q2 2015 was First Eagle Investment Management, an estimated $425K sold.
Based on aggregated 13F filings for Q2 2015.